3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Lymphoid
1
Conditions
Neoplasms
1
Interventions
pembrolizumab
55
Specimen Handling
28
Biopsy
28
Magnetic Resonance Spectroscopy
26
Paclitaxel
23
Blood Specimen Collection
22
Nivolumab
20
atezolizumab
18
Standard of Care
18
Carboplatin
18
Surveys and Questionnaires
17
Bevacizumab
17
Oxaliplatin
13
Fluorouracil
13
Cisplatin
13
Radiotherapy
12
Radiosurgery
12
Cyclophosphamide
12
Pemetrexed
11
Leucovorin
11
Irinotecan
10
Gemcitabine
10
Docetaxel
10
Capecitabine
10
trastuzumab deruxtecan
8
olaparib
8
durvalumab
8
Taxes
8
Ipilimumab
8
Trastuzumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
sacubitril and valsartan sodium hydrate drug combination
×
Tumor-Agnostic
×
1 year
×
Clear all
NCT03872778
2026-04-30
NeoRay
Advanced Accelerator Applications
Phase 1/2
Completed
35 enrolled